Anupam Rasayan India Limited completed the Bliss GVS Pharma Limited acquisition on September 28, 2026, holding approximately 50.07%. Q2 FY27 total income was INR821 crores and EBITDA INR202 crores, up 11% and 41% year-on-year, with a 25% margin.

4 source passages

Ladies and gentlemen, good day, and welcome to the Q2 and H1 FY27 Earnings Call for Anupam Rasayan India Limited. Completion of Bliss GVS Pharma acquisition as on September 28, 2026, marks an important milestone in our journey towards building an integrated pharmaceutical platform. Anupam Rasayan now holds approximately 50.07% of the equity capital of Bliss GVS Pharma. Total income for the quarter stood at INR821 crores compared to INR739 crores in the corresponding quarter last year, registering a strong growth of 11% year-on-year. EBITDA for the quarter stood at INR202 crores compared to INR144 crores in Q2FY26, representing a growth of 41% year-on-year. Our consolidated EBITDA margin improved to 25% in Q2 FY27 compared to 19% in the corresponding quarter last year, while H1 margins improved from 26% from 22%. Open the document at this passage

Aug 14

Earnings call

Q1 2027 earnings call AI summary on its way

May 25

Earnings call

Q4 2026 earnings call AI summary on its way

Showing 1–3 of 3 documents